Fulcrum shares drop 52 percent as sickle-cell drug ends
Fulcrum shares fell 52 percent after it scrapped a sickle-cell drug over FDA cancer concerns. The company is now exploring a potential sale or merger.
Insights:
Fulcrum Therapeutics fell 52% on Tuesday after abandoning development of its sickle-cell disease drug, pociredir, following FDA cancer-risk concerns. The company is now exploring strategic options, including a potential sale or merger, to preserve its remaining capital. This discontinuation follows a series of safety-related setbacks for sickle-cell treatments, including the 2024 withdrawal of Oxbryta by Pfizer.
